Biogen beats quarterly estimates as newer drugs fuel growth
Reported by Yahoo Finance · finance.yahoo.com · July 29, 2026
July 29 () - Biogen reported second-quarter profit and revenue that topped Wall Street estimates on Wednesday, driven by strong demand for its rare-disease medicines, while sales of its legacy multiple sclerosis drugs stayed under pressure. Investors are closely watching whether recent deals and newer products including its Alzheimer
What the tape says
What to watch: Biogen Inc. (BIIB) beat estimates — check whether the reaction already prices in the surprise before chasing it.
Market reaction today: $BIIB +0.62%
Tone and severity are deterministic keyword classification — not a prediction, a member vote, or a recommendation. Figures are extracted from the headline as published. Wook does not republish Yahoo Finance's reporting.
Your read
Discussion
No one has weighed in yet. Start the discussion on this story.
Headline and link are attributed to Yahoo Finance. Wook of Wall Street is an independent research tool and is not affiliated with Yahoo Finance. Nothing here is financial advice or a recommendation — research and educational content only.